Portfolio company
Affinia Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops rationally designed gene therapies and viral vectors for patients with heart and central nervous system diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Stridebio
This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.
Neurogene Inc
This company develops genetic medicines and gene therapies to treat patients and families affected by rare neurological diseases including Rett syndrome and Batten disease.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Audentes Therapeutics
The company develops gene therapy products to treat patients with serious and rare neuromuscular diseases.
Phlox Therapeutics
This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.
Rocket Pharma
This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.
Aera Therapeutics
This biotechnology company develops delivery platforms for genetic medicines to treat various diseases for biopharmaceutical partners and patients.